Strategy & Mission
We’re developing new mechanism antibiotics to become the new standards of care
Summit Therapeutics is a leader in antibiotic innovation
We have a clear strategy: through new science and philosophy, we are creating new opportunities to become the standard of care for serious infectious diseases.
Innovation drives success in medicine. In the field of antibiotics research, no new classes of antibiotics have been approved in 15 years. With our promising pipeline and the ability of our Discuva Platform to develop future new mechanism antibiotics, we aim to change that.
Our proprietary Discuva Platform is designed to uncover novel bacterial targets and develops new mechanism antibiotics against them. To date, the Discuva Platform has developed two new targets for gonorrhoea, an ESKAPE programme and undisclosed programmes with Roche.
In addition, ridinilazole, our Phase 3 new mechanism antibiotic for C. difficile infection (‘CDI’), is being supported by an award worth up to $62 million from BARDA.
We think about antibiotics differently. We design our new mechanism antibiotics to be specific for the pathogen or infection. We believe this allows us to develop antibiotics capable of meeting the unmet needs of patients and healthcare providers, show clear advantages over current therapies and create value for payors and healthcare systems. We aim to develop antibiotics for high-volume use, not to be held in reserve. Our targeted approach supports antibiotic stewardship, improved outcomes for patients and healthcare savings.
We believe our strategy creates new opportunities that are untapped in the antibiotics space. We have the potential to develop antibiotics that beat out the current standards of care and ultimately achieve commercial success. We plan to execute this strategy by becoming a fully integrated, global biopharmaceutical company. Our experienced team of scientists, clinical and regulatory developers and executives spans the drug development spectrum, from research through commercialisation.
Summit was founded in 2003 and our shares are listed on the Nasdaq Global Market (symbol ‘SMMT’) and the AIM Market of the London Stock Exchange (symbol ‘SUMM’). We are headquartered in Oxfordshire, UK, and have offices in Cambridge, Massachusetts, US, and Cambridge, UK.